CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Mr. Harish  Shantharam C.F.A.

Chief Financial Officer, Principal Accounting & Financial Officer

Ms. Becki  Filice

Senior Vice President of Portfolio & Product Leadership

Mr. Paul T. Quinlan

General Counsel, Chief Compliance Officer & Corporate Secretary

Dr. Charles A. McWherter Ph.D.

President of Research & Development and Chief Scientific Officer

Dr. Robert L. Martin

Senior Vice President of Manufacturing & Nonclinical Development

Ms. Klara A. Dickinson-Eason

Chief Regulatory & Quality Assurance Officer

Mr. Patrick J. O'Mara

Senior Vice President of Business Development

Mr. Ben  Kozub

Head of Commercial

Mr. Ken  Boehm

Senior Vice President of Human Resources

Mr. Sujal A. Shah

President, Chief Executive Officer & Director

Biotechnologia

CymaBay Therapeutics, Inc.

CymaBay Therapeutics, Inc. Struktura zarządzania

Informacje o kierownictwie